1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Medicine
  4. Volume 66, 2015
  5. Article

Annual Review of Medicine

Volume 66, 2015

ADAMTS13 and von Willebrand Factor in Thrombotic Thrombocytopenic Purpura

Abstract

Pathogenesis of thrombotic thrombocytopenic purpura (TTP) was a mystery for over half a century until the discovery of ADAMTS13. ADAMTS13 is primarily synthesized in the liver, and its main function is to cleave von Willebrand factor (VWF) anchored on the endothelial surface, in circulation, and at the sites of vascular injury. Deficiency of plasma ADAMTS13 activity (<10%) resulting from mutations of the gene or autoantibodies against ADAMTS13 causes hereditary or acquired (idiopathic) TTP. ADAMTS13 activity is usually normal or modestly reduced (>20%) in other forms of thrombotic microangiopathy secondary to hematopoietic progenitor cell transplantation, infection, and disseminated malignancy or in hemolytic uremic syndrome. Plasma infusion or exchange remains the initial treatment of choice to date, but novel therapeutics such as recombinant ADAMTS13 and gene therapy are under development. Moreover, ADAMTS13 deficiency has been shown to be a risk factor for the development of myocardial infarction, stroke, cerebral malaria, and preeclampsia.

Keyword(s): arterial thrombosis, autoantibodies, autoimmune disorder, metalloprotease, mutations, rare hematological disease
Loading

Article metrics loading...

/content/journals/10.1146/annurev-med-061813-013241
2015-01-14
2024-04-16
Loading full text...

Full text loading...

/deliver/fulltext/med/66/1/annurev-med-061813-013241.html?itemId=/content/journals/10.1146/annurev-med-061813-013241&mimeType=html&fmt=ahah

Literature Cited

  1. Moschcowitz E.1.  1924. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease. Proc. N.Y. Pathol. Soc. 24:21–24 [Google Scholar]
  2. Schulman I, Pierce M, Lukens A. 2.  et al. 1960. Studies on thrombopoiesis. I. A factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency. Blood 16:943–57 [Google Scholar]
  3. Upshaw JD Jr. 3.  1978. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N. Engl. J. Med. 298:1350–25 [Google Scholar]
  4. Rennard S, Abe S. 4.  1979. Decreased cold-insoluble globulin in congenital thrombocytopenia (Upshaw-Schulman syndrome). N. Engl. J. Med. 300:368 [Google Scholar]
  5. Kinoshita S, Yoshioka A, Park YD. 5.  et al. 2001. Upshaw-Schulman syndrome revisited: a concept of congenital thrombotic thrombocytopenic purpura. Int. J. Hematol. 74:101–8 [Google Scholar]
  6. Amorosi E, Ultmann J. 6.  1966. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine 45:139–59 [Google Scholar]
  7. Bell WR, Braine HG, Ness PM. 7.  et al. 1991. Improved survival in thrombotic thrombocytopenic purpura–hemolytic uremic syndrome. Clinical experience in 108 patients. N. Engl. J. Med. 325:398–403 [Google Scholar]
  8. Tsai HM, Lian EC. 8.  1998. Antibodies to von Willebrand factor–cleaving protease in acute thrombotic thrombocytopenic purpura. N. Engl. J. Med. 339:1585–94 [Google Scholar]
  9. Rock GA, Shumak KH, Buskard NA. 9.  et al. 1991. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N. Engl. J. Med. 325:393–97 [Google Scholar]
  10. Moake JL, Rudy CK, Troll JH. 10.  et al. 1982. Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N. Engl. J. Med. 307:1432–35 [Google Scholar]
  11. Furlan M, Robles R, Solenthaler M. 11.  et al. 1997. Deficient activity of von Willebrand factor–cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 89:3097–103 [Google Scholar]
  12. Furlan M, Robles R, Solenthaler M. 12.  et al. 1998. Acquired deficiency of von Willebrand factor–cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 91:2839–46 [Google Scholar]
  13. Furlan M, Robles R, Lammle B. 13.  1996. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87:4223–34 [Google Scholar]
  14. Tsai HM.14.  1996. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 87:4235–44 [Google Scholar]
  15. Fujikawa K, Suzuki H, McMullen B. 15.  et al. 2001. Purification of human von Willebrand factor–cleaving protease and its identification as a new member of the metalloproteinase family. Blood 98:1662–66 [Google Scholar]
  16. Gerritsen HE, Robles R, Lammle B. 16.  et al. 2001. Partial amino acid sequence of purified von Willebrand factor–cleaving protease. Blood 98:1654–61 [Google Scholar]
  17. Zheng X, Chung D, Takayama TK. 17.  et al. 2001. Structure of von Willebrand factor–cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J. Biol. Chem. 276:41059–63 [Google Scholar]
  18. Levy GG, Nichols WC, Lian EC. 18.  et al. 2001. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413:488–94 [Google Scholar]
  19. Plaimauer B, Zimmermann K, Volkel D. 19.  et al. 2002. Cloning, expression, and functional characterization of the von Willebrand factor–cleaving protease (ADAMTS13). Blood 100:3626–32 [Google Scholar]
  20. Zheng X, Nishio K, Majerus EM. 20.  et al. 2003. Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13. J. Biol. Chem. 278:30136–41 [Google Scholar]
  21. Dong JF, Moake JL, Nolasco L. 21.  et al. 2002. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 100:4033–39 [Google Scholar]
  22. Rieger M, Ferrari S, Kremer Hovinga JA. 22.  et al. 2006. Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA). Thromb. Haemost. 95:212–20 [Google Scholar]
  23. Uemura M, Tatsumi K, Matsumoto M. 23.  et al. 2005. Localization of ADAMTS13 to the stellate cells of human liver. Blood 106:922–24 [Google Scholar]
  24. Zhou W, Inada M, Lee TP. 24.  et al. 2005. ADAMTS13 is expressed in hepatic stellate cells. Lab. Invest. 85:780–88 [Google Scholar]
  25. Niiya M, Uemura M, Zheng XW. 25.  et al. 2006. Increased ADAMTS-13 proteolytic activity in rat hepatic stellate cells upon activation in vitro and in vivo. J. Thromb. Haemost. 4:1063–70 [Google Scholar]
  26. Watanabe N, Ikeda H, Kume Y. 26.  et al. 2009. Increased production of ADAMTS13 in hepatic stellate cells contributes to enhanced plasma ADAMTS13 activity in rat models of cholestasis and steatohepatitis. Thromb. Haemost. 102:389–96 [Google Scholar]
  27. Kume Y, Ikeda H, Inoue M. 27.  et al. 2007. Hepatic stellate cell damage may lead to decreased plasma ADAMTS13 activity in rats. FEBS Lett. 581:1631–34 [Google Scholar]
  28. Shang D, Zheng XW, Niiya M. 28.  et al. 2006. Apical sorting of ADAMTS13 in vascular endothelial cells and Madin-Darby canine kidney cells depends on the CUB domains and their association with lipid rafts. Blood 108:2207–15 [Google Scholar]
  29. Suzuki M, Murata M, Matsubara Y. 29.  et al. 2004. Detection of von Willebrand factor–cleaving protease (ADAMTS-13) in human platelets. Biochem. Biophys. Res. Commun. 313:212–16 [Google Scholar]
  30. Manea M, Kristoffersson A, Schneppenheim R. 30.  et al. 2007. Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura. Br. J. Haematol. 138:651–62 [Google Scholar]
  31. Tauchi R, Imagama S, Ohgomori T. 31.  et al. 2012. ADAMTS-13 is produced by glial cells and upregulated after spinal cord injury. Neurosci. Lett. 517:1–6 [Google Scholar]
  32. Mannucci PM, Capoferri C, Canciani MT. 32.  2004. Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease. Br. J. Haematol. 126:213–18 [Google Scholar]
  33. Cao WJ, Niiya M, Zheng XW. 33.  et al. 2008. Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells. J. Thromb. Haemost. 6:1233–35 [Google Scholar]
  34. Westwood JP, Langley K, Heelas E. 34.  et al. 2014. Complement and cytokine response in acute thrombotic thrombocytopenic purpura. Br. J. Haematol. 164:858–66 [Google Scholar]
  35. Shen L, Lu G, Dong N. 35.  et al. 2013. Simvastatin increases ADAMTS13 expression in podocytes. Thromb. Res. 132:94–99 [Google Scholar]
  36. Borchiellini A, Fijnvandraat K, ten Cate JW. 36.  et al. 1996. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans. Blood 88:2951–58 [Google Scholar]
  37. Hattori R, Hamilton KK, McEver RP. 37.  et al. 1989. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J. Biol. Chem. 264:9053–60 [Google Scholar]
  38. Huang J, Motto DG, Bundle DR. 38.  et al. 2010. Shiga toxin B subunits induce VWF secretion by human endothelial cells and thrombotic microangiopathy in ADAMTS13-deficient mice. Blood 116:3653–59 [Google Scholar]
  39. Bao J, Xiao J, Mao Y. 39.  et al. 2014. Carboxyl terminus of ADAMTS13 directly inhibits platelet aggregation and ultra large von Willebrand factor string formation under flow in a free-thiol-dependent manner. Arterioscler. Thromb. Vasc. Biol. 34:397–407 [Google Scholar]
  40. Mannucci PM.40.  2000. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first twenty years. Haemophilia 6:Suppl. 160–67 [Google Scholar]
  41. Choi H, Aboulfatova K, Pownall HJ. 41.  et al. 2007. Shear-induced disulfide bond formation regulates adhesion activity of von Willebrand factor. J. Biol. Chem. 282:35604–11 [Google Scholar]
  42. Yeh HC, Zhou Z, Choi H. 42.  et al. 2010. Disulfide bond reduction of von Willebrand factor by ADAMTS-13. J. Thromb. Haemost. 8:2778–88 [Google Scholar]
  43. McGrath RT, van den Biggelaar M, Byrne B. 43.  et al. 2013. Altered glycosylation of platelet-derived von Willebrand factor confers resistance to ADAMTS13 proteolysis. Blood 122:4107–10 [Google Scholar]
  44. Majerus EM, Anderson PJ, Sadler JE. 44.  2005. Binding of ADAMTS13 to von Willebrand factor. J. Biol. Chem. 280:21773–78 [Google Scholar]
  45. Jin SY, Skipwith CG, Shang D. 45.  et al. 2009. von Willebrand factor cleaved from endothelial cells by ADAMTS13 remains ultralarge in size. J. Thromb. Haemost. 7:1749–52 [Google Scholar]
  46. Skipwith CG, Cao W, Zheng XL. 46.  2010. Factor VIII and platelets synergistically accelerate cleavage of von Willebrand factor by ADAMTS13 under fluid shear stress. J. Biol. Chem. 285:28596–603 [Google Scholar]
  47. Cao W, Krishnaswamy S, Camire RM. 47.  et al. 2008. Factor VIII accelerates proteolytic cleavage of von Willebrand factor by ADAMTS13. Proc. Natl. Acad. Sci. USA 105:7416–21 [Google Scholar]
  48. Furlan M, Robles R, Galbusera M. 48.  et al. 1998. von Willebrand factor–cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N. Engl. J. Med. 339:1578–84 [Google Scholar]
  49. Zhang X, Halvorsen K, Zhang CZ. 49.  et al. 2009. Mechanoenzymatic cleavage of the ultralarge vascular protein von Willebrand factor. Science 324:1330–34 [Google Scholar]
  50. Lynch CJ, Lane DA, Luken BM. 50.  2014. Control of VWF A2 domain stability and ADAMTS13 access to the scissile bond of full-length VWF. Blood 123:2585–92 [Google Scholar]
  51. Xu AJ, Springer TA. 51.  2012. Calcium stabilizes the von Willebrand factor A2 domain by promoting refolding. Proc. Natl. Acad. Sci. USA 109:3742–47 [Google Scholar]
  52. Tao Z, Wang Y, Choi H. 52.  et al. 2005. Cleavage of ultralarge multimers of von Willebrand factor by C-terminal-truncated mutants of ADAMTS-13 under flow. Blood 106:141–43 [Google Scholar]
  53. Ai J, Smith P, Wang S. 53.  et al. 2005. The proximal carboxyl-terminal domains of ADAMTS13 determine substrate specificity and are all required for cleavage of von Willebrand factor. J. Biol. Chem. 280:29428–34 [Google Scholar]
  54. Jin SY, Skipwith CG, Zheng XL. 54.  2010. Amino acid residues Arg(659), Arg(660), and Tyr(661) in the spacer domain of ADAMTS13 are critical for cleavage of von Willebrand factor. Blood 115:2300–10 [Google Scholar]
  55. Gao W, Anderson PJ, Sadler JE. 55.  2008. Extensive contacts between ADAMTS13 exosites and von Willebrand factor domain A2 contribute to substrate specificity. Blood 112:1713–19 [Google Scholar]
  56. Zhang P, Pan W, Rux AH. 56.  et al. 2007. The cooperative activity between the carboxyl-terminal TSP1 repeats and the CUB domains of ADAMTS13 is crucial for recognition of von Willebrand factor under flow. Blood 110:1887–94 [Google Scholar]
  57. Tao Z, Peng Y, Nolasco L. 57.  et al. 2005. Recombinant CUB-1 domain polypeptide inhibits the cleavage of ULVWF strings by ADAMTS13 under flow conditions. Blood 106:4139–45 [Google Scholar]
  58. Banno F, Chauhan AK, Kokame K. 58.  et al. 2009. The distal carboxyl-terminal domains of ADAMTS13 are required for regulation of in vivo thrombus formation. Blood 113:5323–29 [Google Scholar]
  59. Xiao J, Jin SY, Xue J. 59.  et al. 2011. Essential domains of a disintegrin and metalloprotease with thrombospondin type 1 repeats-13 metalloprotease required for modulation of arterial thrombosis. Arterioscler. Thromb. Vasc. Biol. 31:2261–69 [Google Scholar]
  60. Zheng XL, Wu HM, Shang D. 60.  et al. 2010. Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica 95:1555–62 [Google Scholar]
  61. Zheng XL.61.  2013. Structure-function and regulation of ADAMTS-13 protease. J. Thromb. Haemost. 11:Suppl. 111–23 [Google Scholar]
  62. Pos W, Sorvillo N, Fijnheer R. 62.  et al. 2011. Residues Arg568 and Phe592 contribute to an antigenic surface for anti-ADAMTS13 antibodies in the spacer domain. Haematologica 96:1670–77 [Google Scholar]
  63. Jian C, Xiao J, Gong L. 63.  et al. 2012. Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura. Blood 119:3836–43 [Google Scholar]
  64. Arbus GS.64.  1997. Association of verotoxin-producing E. coli and verotoxin with hemolytic uremic syndrome. Kidney Int. Suppl. 58:S91–96 [Google Scholar]
  65. Kavanagh D, Goodship TH, Richards A. 65.  2013. Atypical hemolytic uremic syndrome. Semin. Nephrol. 33:508–30 [Google Scholar]
  66. Dragon-Durey MA, Blanc C, Garnier A. 66.  et al. 2010. Anti–factor H autoantibody-associated hemolytic uremic syndrome: review of literature of the autoimmune form of HUS. Semin. Thromb. Hemost. 36:633–40 [Google Scholar]
  67. Kavanagh D, Pappworth IY, Anderson H. 67.  et al. 2012. Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon?. Clin. J. Am. Soc. Nephrol. 7:417–26 [Google Scholar]
  68. Delvaeye M, Noris M, De Vriese A. 68.  et al. 2009. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 361:345–57 [Google Scholar]
  69. Lemaire M, Fremeaux-Bacchi V, Schaefer F. 69.  et al. 2013. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat. Genet. 45:531–36 [Google Scholar]
  70. Zheng XL, Kaufman RM, Goodnough LT. 70.  et al. 2004. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 103:4043–49 [Google Scholar]
  71. Coppo P, Wolf M, Veyradier A. 71.  et al. 2006. Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br. J. Haematol. 132:66–74 [Google Scholar]
  72. Barrows BD, Teruya J. 72.  2014. Use of the ADAMTS13 activity assay improved the accuracy and efficiency of the diagnosis and treatment of suspected acquired thrombotic thrombocytopenic purpura. Arch. Pathol. Lab. Med. 138:546–49 [Google Scholar]
  73. Furlan M, Lammle B. 73.  1998. Deficiency of von Willebrand factor–cleaving protease in familial and acquired thrombotic thrombocytopenic purpura. Baillieres Clin. Haemat. 11:509–14 [Google Scholar]
  74. Gerritsen HE, Turecek PL, Schwarz HP. 74.  et al. 1999. Assay of von Willebrand factor (vWF)–cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb. Haemost. 82:1386–89 [Google Scholar]
  75. Knovich MA, Lawson HL, Burke MH. 75.  et al. 2008. Rapid quantitative assay of ADAMTS13 activity on an automated coagulation analyzer: clinical applications and comparison with immunoblot method. Am. J. Hematol. 83:654–56 [Google Scholar]
  76. Kokame K, Nobe Y, Kokubo Y. 76.  et al. 2005. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br. J. Haematol. 129:93–100 [Google Scholar]
  77. Kremer Hovinga JA, Vesely SK, Terrell DR. 77.  et al. 2010. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 115:1500–11 [Google Scholar]
  78. Meyer SC, Sulzer I, Lammle B. 78.  et al. 2007. Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies. J. Thromb. Haemost. 5:866–67 [Google Scholar]
  79. Muia J, Gao W, Haberichter SL. 79.  et al. 2013. An optimized fluorogenic ADAMTS13 assay with increased sensitivity for the investigation of patients with thrombotic thrombocytopenic purpura. J. Thromb. Haemost. 11:1511–18 [Google Scholar]
  80. Studt JD, Kremer Hovinga JA, Antoine G. 80.  et al. 2005. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood 105:542–44 [Google Scholar]
  81. Mancini I, Valsecchi C, Lotta LA. 81.  et al. 2014. FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients. Thromb. Haemost. 112:297–303 [Google Scholar]
  82. Mackie I, Langley K, Chitolie A. 82.  et al. 2013. Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies. Thromb. Haemost. 109:488–96 [Google Scholar]
  83. Bianchi V, Robles R, Alberio L. 83.  et al. 2002. Von Willebrand factor–cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 100:710–13 [Google Scholar]
  84. Ono T, Mimuro J, Madoiwa S. 84.  et al. 2006. Severe secondary deficiency of von Willebrand factor–cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 107:528–34 [Google Scholar]
  85. Furlan M, Lammle B. 85.  2001. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor–cleaving protease. Best Prac. Res. Clin. Haemat. 14:437–54 [Google Scholar]
  86. Niiya M, Endo M, Shang D. 86.  et al. 2009. Correction of ADAMTS13 deficiency by in utero gene transfer of lentiviral vector encoding ADAMTS13 genes. Mol. Ther. 17:34–41 [Google Scholar]
  87. Laje P, Shang D, Cao W. 87.  et al. 2009. Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell–mediated gene therapy. Blood 113:2172–80 [Google Scholar]
  88. Jin SY, Xiao J, Bao J. 88.  et al. 2013. AAV-mediated expression of an ADAMTS13 variant prevents shigatoxin-induced thrombotic thrombocytopenic purpura. Blood 121:3825–29, S1–3 [Google Scholar]
  89. Cataland SR, Wu HM. 89.  2014. How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome. Blood 123:2478–84 [Google Scholar]
  90. Wu TC, Yang S, Haven S. 90.  et al. 2013. Complement activation and mortality during an acute episode of thrombotic thrombocytopenic purpura. J. Thromb. Haemost. 11:1925–27 [Google Scholar]
  91. Caramazza D, Quintini G, Abbene I. 91.  et al. 2010. Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: the role of rituximab. Transfusion 50:2753–60 [Google Scholar]
  92. Callewaert F, Roodt J, Ulrichts H. 92.  et al. 2012. Evaluation of efficacy and safety of the anti-VWF nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood 120:3603–10 [Google Scholar]
  93. Knobl P, Jilma B, Gilbert JC. 93.  et al. 2009. Anti–von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura. Transfusion 49:2181–85 [Google Scholar]
  94. Matsukawa M, Kaikita K, Soejima K. 94.  et al. 2007. Serial changes in von Willebrand factor–cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction. Am. J. Cardiol. 100:758–63 [Google Scholar]
  95. Hanson E, Jood K, Nilsson S. 95.  et al. 2009. Association between genetic variation at the ADAMTS13 locus and ischemic stroke. J. Thromb. Haemost. 7:2147–48 [Google Scholar]
  96. Stepanian A, Cohen-Moatti M, Sanglier T. 96.  et al. 2011. Von Willebrand factor and ADAMTS13: a candidate couple for preeclampsia pathophysiology. Arterioscler. Thromb. Vasc. Biol. 31:1703–9 [Google Scholar]
  97. Larkin D, de Laat B, Jenkins PV. 97.  et al. 2009. Severe Plasmodium falciparum malaria is associated with circulating ultra-large von Willebrand multimers and ADAMTS13 inhibition. PLOS Pathog. 5:e1000349 [Google Scholar]
  98. Fujioka M, Hayakawa K, Mishima K. 98.  et al. 2010. ADAMTS13 gene deletion aggravates ischemic brain damage: a possible neuroprotective role of ADAMTS13 by ameliorating postischemic hypoperfusion. Blood 115:1650–53 [Google Scholar]
  99. Gandhi C, Khan MM, Lentz SR. 99.  et al. 2012. ADAMTS13 reduces vascular inflammation and the development of early atherosclerosis in mice. Blood 119:2385–91 [Google Scholar]
  100. Jin SY, Tohyama J, Bauer RC. 100.  et al. 2012. Genetic ablation of Adamts13 gene dramatically accelerates the formation of early atherosclerosis in a murine model. Arterioscler. Thromb. Vasc. Biol. 32:1817–23 [Google Scholar]
/content/journals/10.1146/annurev-med-061813-013241
Loading
ADAMTS13 and von Willebrand Factor in Thrombotic Thrombocytopenic Purpura
Annual Review of Medicine 66, 211 (2015); https://doi.org/10.1146/annurev-med-061813-013241
/content/journals/10.1146/annurev-med-061813-013241
/content/journals/10.1146/annurev-med-061813-013241
Loading

Data & Media loading...

  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error